Sarepta Therapeutics Inc (SRPT) Q1 2026 Earnings Call Transcript

Why It Matters

The guidance underscores Sarepta’s reliance on ELEVIDYS adoption and its ability to sustain profitability amid inventory charges, while pipeline advances and leadership transition shape long‑term shareholder value.

Key Takeaways

• Cash reached $954M, up $89M YoY.
• 2025 net product revenue $1.86B, 16% growth.
• 2026 revenue guidance $1.2‑$1.4B, low‑end modeling.
• ELEVIDYS Q4 $110M hit by flu season.
• SiRNA pipeline advances five clinical programs.

Pulse Analysis

Sarepta entered 2026 with a robust balance sheet, bolstered by $954 million in cash and a 16% revenue jump to $2.2 billion in 2025. The company’s guidance of $1.2‑$1.4 billion for net product revenue reflects a cautious, low‑end modeling approach, yet management remains confident of achieving non‑GAAP operating profit and positive cash flow. This financial discipline comes after a $193 million Q4 inventory charge and the refinancing of 2027 notes into 2030, actions that improve liquidity and reduce near‑term debt pressure.

Commercially, Sarepta’s flagship gene therapy ELEVIDYS faces short‑term headwinds. A severe flu season and six postponed infusions depressed Q4 sales to $110 million, prompting a flat‑to‑‑15% revenue outlook for Q1 2026. The company responded by securing a traditional FDA label for ambulatory patients and launching the product in Japan, unlocking a $40 million milestone from Roche. Management’s education initiatives aim to close the information deficit that emerged after 2025 safety events, with expectations that demand will rebound in the second half of the year.

Beyond existing therapies, Sarepta’s pipeline is a key growth engine. Five siRNA programs—targeting DM1, FSHD, IPF, SCA2, and Huntington’s disease—are advancing toward proof‑of‑concept readouts, while the ESSENCE study may pave the way for traditional approvals of AMONDYS and VYONDYS. The announced CEO transition, with Douglas Ingram retiring by year‑end, adds a governance dimension, but the ongoing search for a successor signals continuity. Collectively, these factors position Sarepta to leverage its diversified portfolio and sustain long‑term value creation.